Global, Regional, and National Estimates of Adult Respiratory and Cardiorespiratory Hospitalisations Attributable to Respiratory Syncytial Virus From 2015 to 2022: Application of the Global Burden of Disease Framework
Katrin Burkart(University of Washington), Elizabeth Begier(Pfizer (United States)), Christopher Gillespie(Institute for Health Metrics and Evaluation), Jam Suba(University of Washington), Ana Gabriela Grajales(Pfizer (Canada)), Andreas Palmborg(Pfizer (United States)), Kejal Hasmukharay(University of Malaya), Quinn Rafferty(Institute for Health Metrics and Evaluation), Caroline Lade(Pfizer (Germany)), Caihua Liang(Pfizer (United States)), sam rogers(Pfizer (United States)), Juan Manuel Reyes(Pfizer (United States)), Asuka Yoshida(Pfizer (United States)), Bradford D. Gessner(Pfizer (United States)), Andreina Jose Alamo(Pfizer (United States)), Zirk Wiid(Pfizer (United States)), Andrei Oros(Institute for Health Metrics and Evaluation), Karan Thakkar(Pfizer (United States)), Kristian Lie(Pfizer (United States))
Cited by 0
Related Papers
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.1k
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021
|The Lancet Rheumatology|2023|1.7k
Health and economic impact of air pollution in the states of India: the Global Burden of Disease Study 2019
|The Lancet Planetary Health|2020|707
Estimating the cause-specific relative risks of non-optimal temperature on daily mortality: a two-part modelling approach applied to the Global Burden of Disease Study
|The Lancet|2021|391
Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019
|The Lancet Infectious Diseases|2022|312